



---

**3<sup>rd</sup> BELGIAN LEFT ATRIAL  
APPENDAGE  
OCCLUSION MEETING**

Friday 23.11.2018

Hotel Dolce La Hulpe Brussels

---



## MEETING OBJECTIVES

Dear Colleagues,

Oral anticoagulation remains the mainstay of therapy for stroke prevention in patients with atrial fibrillation. However, a significant proportion of patients at risk of stroke can not tolerate these drugs because of significant side effects, including bleeding complications. Percutaneous left atrial appendage occlusion (LAAO) is increasingly recognized as a valid alternative to oral anticoagulation in patients at risk of stroke and with previous major bleeding events or at high bleeding risk.

LAAO is still at an early phase in many centers in Belgium and we need to provide a concise overview of the current evidence together with key messages about optimal imaging and implantation, prevention and management of complications.

This half-day course is designed to give you an overview on all aspects of this treatment modality and on how to select patients optimally.

We look forward to seeing you in La Hulpe,

On behalf of the Scientific Committee

Adel Aminian, MD

## PROGRAMME

**12:30-13:20** Welcome lunch

**13:20-13:30** Introduction and meeting objectives  
*Dr Adel Aminian, CHU Charleroi, BE*

**Part 1: Clinical update on stroke prevention - Current indications for oral anticoagulant therapy and LAAO**

*Chairs: Prof Werner Budts, UZ Leuven, BE  
Dr Adel Aminian, CHU Charleroi, BE*

**13:30** Direct oral anticoagulant therapy for stroke prevention in AF patients: clinical update, real-world uptake and remaining limitations  
*Prof Freek W.A. Verheugt, Hartcentrum OLVG Amsterdam, NL*

**13:50** Device-based LAA closure in 2018: current state of the evidence and ongoing important trials  
*Prof Martin Bergmann, Cardiologikum Hamburg, DE*

**14:10** Stroke prevention in AF patients with renal failure: current challenges  
*Dr Jean-Michel Hougardy, Erasme Hospital, BE*

**14:20** Recurrent stroke despite OAC therapy: is there a place for LAAO?  
*Prof Apostolos Tzikas, AHEPA University Hospital Thessaloniki, GR*

**14:30** Panel discussion

**Part 2: Patient selection for LAAO - “Real-world” case review session**

*Chairs: Dr Edouard Benit, Hart Centrum Hasselt, BE  
Prof Joëlle Kefer, UCL Saint-Luc, BE*

**14:40** Case 1  
*Dr Edouard Benit, Hart Centrum Hasselt, BE*

## PROGRAMME

- 14:50** Case 2  
Prof Vincent Segers, UZ Antwerp, BE
- 15:00** Case 3  
Prof Joëlle Kefer, UCL Saint-Luc, BE
- 15:10** Coffee Break
- Part 3: Imaging in LAAO**  
*Chairs: Dr Mathieu Lempereur, CHU Liège, BE*  
*Dr Tom De Potter, OLV Ziekenhuis Aalst, BE*
- 15:45** Assessing LAA morphology and size for device selection: should CT become the gold standard?  
Prof Ole de Backer, The Heart Center – Rigshospitalet Copenhagen, DK
- 16:00** Imaging guidance during LAA procedure: from trans-septal puncture to device sizing and placement  
*Dr Didier Stroobants, Jessa Ziekenhuis Hasselt, BE*
- 16:15** Follow-up imaging after LAAO: which imaging modality, when and what to look for?  
*Dr Mathieu Lempereur, CHU Liège, BE*
- 16:30** Use of integrated 3D TEE-Fluoroscopy for guidance of LAA closure  
*Dr Adel Aminian, CHU Charleroi, BE*
- 16:40** Panel discussion

## PROGRAMME

### **Part 4: Prevention of complications during and after LAAO**

*Chairs: Prof Joëlle Kefer, UCL Saint-Luc Brussels, BE  
Prof Paul Vermeersch, ZNA Middelheim  
Antwerp, BE*

**16:50** Prevention and management of complications during LAAO: focus on pericardial effusion and device embolization  
*Prof Apostolos Tzikas, AHEPA University Hospital Thessaloniki, GR*

**17:05** Implantations strategies in complex anatomies  
*Prof Ole de Backer, The Heart Center – Rigshospitalet Copenhagen, DK*

**17:20** LAAO device-related thrombosis: clinical update and preventive strategies  
*Dr Adel Aminian, CHU Charleroi, BE*

**17:35** Panel discussion

### **Part 5: Registry update**

*Chairs: Dr Adel Aminian, CHU Charleroi, BE  
Prof Paul Vermeersch, ZNA Middelheim  
Antwerp, BE*

**17:45** Update on the Belgian LAAO registry and reimbursement status  
*Prof Joëlle Kefer, UCL Saint-Luc Brussels, BE*

**17:55** Panel discussion

**18:00** Conclusions and future steps

**18:05** Adjourn

## REGISTRATION

VISIT OUR WEBSITE

[www.blaao.be](http://www.blaao.be)

Online registration is open!

Accreditation



RIZIV INAMI

ORGANISING SECRETARIAT



**Downtown Europe**

Professional Congress Organisers

[blaao@downtowneurope.be](mailto:blaao@downtowneurope.be)

Tel: +32 2 732 35 20

## PRACTICAL INFORMATION



### Registration

Registration to the meeting is free of charge but compulsory. The number of seats being limited, registrations will be accepted on a first come first served basis.

### Venue

Dolce La Hulpe Brussels, 135 Chaussée de Bruxelles, 1310 La Hulpe.

### Parking

Free large parking is available in the park of the hotel.

### Welcome desk

The welcome desk will be open from 12.30 on 23<sup>rd</sup> November 2018.

### Badges

Badges will be provided at the welcome desk. All participants will be requested to wear their badge throughout the meeting.

### Lunch

Lunch buffet will be offered at the venue from 12.30 until 13.20.

### Language

Presentations will be given in English.

## SCIENTIFIC COMMITTEE

- Adel Aminian, CHU Charleroi
- Edouard Benit, Hearth Center Hasselt
- Werner Budts, UZ Leuven
- Tom De Potter, OLV Aalst
- Joëlle Kefer, UCL Brussels
- Mathieu Lempereur, CHU Liège
- Paul Vermeersch, ZNA Middelheim

IN COLLABORATION WITH



## MAJOR SPONSORS



## SPONSORS



Bristol-Myers Squibb



TERUMO